Maryam Gondal, MD
Internal Medicine · New Haven, CTNPI 1003163593
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,200 of the $1,672 with a category attached, or 71.8%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 73.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $1,200 and has fallen 93.4% since, to $79 in 2025.
Across 20 payments — averaging $83.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Fresenius USA Marketing, Inc.$193
- Otsuka America Pharmaceutical, Inc.$61
- Vantive US Healthcare LLC$48
- Akebia Therapeutics Inc$38
- Amgen$35
- plus $66 from 3 others
Across 11 payments — averaging $10,187 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$73K
- AbbVie$39K
What the payments were for
- Consulting fees$1,20072%
- Food & beverage$47228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $1,231 |
| Fresenius USA Marketing, Inc. | 3 | $193 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Vantive US Healthcare LLC | 2 | $48 |
| Akebia Therapeutics Inc | 3 | $38 |
| Amgen | 2 | $35 |
| AstraZeneca | 2 | $32 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $12 |
How this compares
$1,672 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New Haven
- Nancy BrownNew Haven$1.6M
- Richard LiftonNew Haven$160K
- Wayne WarrenNew Haven$127K
- Marcella SmithNew Haven$66K
- Sanjay AggarwalNew Haven$54K
- Bubu BaniniNew Haven$39K
- Sandra SpringerNew Haven$39K
- Karen WangNew Haven$38K
- Michael SchilskyNew Haven$36K
- Kenechukwu MezueNew Haven$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.